BOSENTAN OPTIONS

six The phosphodiesterase-five inhibitor sildenafil is accredited for PAH in FC I–IV within the United states and FC II–III in Europe. Endothelin receptor antagonists (ERAs) which include bosentan, sitaxentan and ambrisentan are oral therapies licensed for use in PAH. As no oral agent has shown superiority there stays discussion concerning whic